Insmed (INSM) Reiterated at Buy by Stifel Amid Returning Focus on Brinsupri Sales

April 8, 2026 7:13 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $208.00 price target on Insmed (NASDAQ: INSM).The analyst commented, "The disclosure ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found